Through May 19, 1972, the National Institute of Arthritis and Metabolic Diseases; until June 23, 1981, the National Institute of Arthritis, Metabolism and Digestive Diseases; and until April 8, 1986, the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases.
- Mission
- Important events
- Legislative chronology
- Director
- Program
Mission
The mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is to conduct and support medical research and research education and disseminate science-based information on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders and obesity; and renal, urological and hematological diseases to improve people's health and quality of life.
general description
The NIDDK supports a wide range of medical research through grants to universities and other medical research institutions across the country. The Institute also supports government scientists conducting basic, translational, and clinical research on a wide range of research topics and serious and chronic diseases and conditions related to the Institute's mission. In addition, the NIDDK supports research training for students and researchers at various stages of their careers, as well as a variety of educational and outreach programs to provide science-based information to patients and their families, health professionals, and the public. public.
External research funded by the NIDDK is divided into three scientific program areas
- Diabetes, endocrinology and metabolic diseases
- Digestive Diseases and Nutrition
- Renal, urological and hematological diseases
The NIDDK's general principles for promoting research include:
- Maintain a vigorous, investigator-driven research portfolio that supports cross-cutting science that can be applied to many disease-specific research areas.
- Support pivotal clinical trials and trials with a focus on substantial participation of higher-risk groups.
- Foster a stable and diverse pool of talented new researchers
- Foster exceptional research training and mentoring opportunities
- Ensure that science-based health information reaches patients, their families, healthcare providers, and the public through public relations and communications.
Important events in the history of the NIDDK
August 15, 1950– President Harry S. Truman signed the Omnibus Medical Research Act, establishing the National Institute of Arthritis and Metabolic Diseases (NIAMD) in the US Public Health Service. The new institute included the laboratories of the Institute for Experimental Biology and Medicine and was expanded to include clinical research on rheumatic diseases, diabetes, and a host of metabolic, hormonal, and gastrointestinal diseases.
November 15, 1950—The National Advisory Council on Arthritis and Metabolic Diseases held its first meeting and recommended approval of the first NIAMD grants.
1959-DR. Arthur Kornberg, former head of the institute's department of enzymes and metabolism, shared the Nobel Prize in Physiology or Medicine with another scientist for the synthesis of nucleic acids.
1961Mobile trailer units equipped with laboratories began an epidemiologic study of arthritis with American Indians of the Blackfeet Nation of Montana, which led to arthritis and diabetes work with the Gila River Indian community in Arizona and the establishment of theNIDDK Phoenix Department of Epidemiology and Clinical Research, where work on type 2 diabetes and obesity continues to this day.
October 16, 1968-DR. Marshall W. Nirenberg of the National Heart Institute shared the Nobel Prize in Physiology or Medicine with two other scientists. dr. Nirenberg reported on his famous partial cracking of the genetic code as a NIAMD scientist.
November 1970—The institute celebrated its 20th anniversary.
May 19, 1972— The name of the institute was changed to the National Institute of Arthritis, Metabolism and Digestive Diseases (NIAMDD).
October 1972- Dr Christian B. Anfinsen, director of the Institute's Chemical Biology Laboratory, shared the Nobel Prize in Chemistry with two other American scientists for demonstrating one of the most simplifying concepts in molecular biology: the three-dimensional conformation of a native protein is determined by the chemistry. of its amino acid sequence. A significant portion of the research cited for the award was conducted while Anfinsen was at the NIH.
September 1973—The establishment of the first Diabetes Endocrinology Research Centers marked the beginning of the Institute's Diabetes Centers program.
November 1975—After nine months of research into the epidemiology and nature of diabetes mellitus and public consultation in the United States, the National Diabetes Commission released its reportLong-term plan to combat diabetes, to congress. Recommendations included expanding and coordinating diabetes and related research programs; Creation of a program of diabetes research and education centers; Accelerate diabetes control, education and health care programs; and the establishment of a national diabetes advisory board.
April 1976– Published by the National Commission on Arthritis and Related Musculoskeletal DiseasesDer Arthritis-Plan. This report to Congress called for increased arthritis research and education programs, multi-use arthritis centers, arthritis epidemiologic studies and data systems, a National Arthritis Information Service, and a National Arthritis Advisory Committee.
October 1976-DR. Baruch S. Blumberg shared the Nobel Prize in Physiology or Medicine with another scientist for his research on infectious diseases. dr. In 1963, Blumberg discovered the hepatitis B virus protein, the "Australian antigen", at the institute. This advance has proven to be a scientific and clinical milestone in the detection and control of viral hepatitis and has led to the development of preventive measures against hepatitis and liver cancer.
April 19, 1977—The NIH director established a trans-NIH diabetes program, led by NIAMDD.
September 1977—More than $5 million in grants have been awarded to five institutions to establish centers for diabetes research and education.
October 1977—In response to the recommendation of the National Commission on Diabetes, the National Diabetes Data Group was established within the Institute to collect, analyze, and share diabetes data with scientific and public health planning and policy associations.
December 1977—Institute fellows Drs. Roger CL Guillemin and Andrew V. Schally shared the Nobel Prize in Physiology or Medicine with a third scientist. The Guillemin and Schally prizes were awarded for discoveries related to the production of peptide hormones in the brain.
1978—In response to language from Congress, the NIDDK launched the National Diabetes Information Clearinghouse to improve knowledge and understanding of diabetes among people with these conditions and their families, health professionals, and the public.
January 1979—The National Commission for Digestive Diseases published the report TheLong-range national plan to combat digestive diseases. Recommendations to Congress included the establishment of a national digestive disease advisory board and clearinghouse, and increased emphasis on digestive disease education programs in medical schools.
June 1980—In response to congressional language, the NIDDK created the National Digestive Diseases Information Clearinghouse to improve knowledge and understanding of digestive diseases among people living with these conditions and their families, health professionals, and the public .
September 1980-DR. Joseph E. Rall, NIAMDD's director of internal research, became the first person from NIH to be appointed with the rank of Distinguished Executive in the Senior Executive Service. President Jimmy Carter presented the award on September 9 at the White House.
October 15, 1980—NIAMDD celebrated its 30th anniversary.
June 23, 1981- The institute was renamed the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases (NIADDK).
April 1982-US. Richard S. Schweiker, Secretary of the Department of Health and Human Services (HHS), elevated NIADDK programs to departmental status and created five extracurricular departments and the Department of Intramural Research.
November 1982-DR. Elizabeth Neufeld, NIADDK Chief of Genetics and Biochemistry, received the Albert Lasker Clinical Medical Research Award. She was born together with Dr. Roscoe O. Brady, of the then National Institute of Neurological and Communication Disorders and Stroke, cited for her contributions to the understanding and diagnosis of inherited disorders called mucopolysaccharide storage disorders.
1982—NIDDK support helped develop an effective vaccine against the virus that causes acute hepatitis B.
1983-HeDiabetes Control and Complications Study(DCCT) begins to show that keeping blood sugar levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve damage caused by diabetes.
November 1984—Six institutions were financed to establish the Silvio O. Conte Basic Research Centers for Digestive Diseases. Research centers study the underlying causes, diagnosis, treatment, and prevention of diseases of the digestive system.
8. April 1986- The Institute's Department of Arthritis, Musculoskeletal and Skin Diseases became the nucleus of the new National Institute of Arthritis, Musculoskeletal and Skin Diseases. The NIADDK was renamed the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
3. June 1986—The National Advisory Board on Urologic and Kidney Diseases was formed to formulate the long-range plan to combat urologic and kidney disease.
1. August 1987— Six institutions were funded to establish the George M. O'Brien Urology and Kidney Research Centers.
December 1987—In response to the congressional survey of NIDDK's fiscal year 1988 grants, the Institute established a program of Cystic Fibrosis Research Centers.
1987—In response to language from Congress, the NIDDK created the National Kidney and Urologic Diseases Information Clearinghouse to increase knowledge and understanding of kidney and urologic system diseases among people living with these conditions and their families, professionals of health and improve publicity.
March 1990—The National Advisory Board on Urologic and Kidney Diseases issued its report,Long-term plan: window to the 21st century.
September 16, 1990—The NIDDK celebrated its 40th anniversary.
June 1991—The NIDDK Advisory Board established the National Task Force on the Prevention and Treatment of Obesity to summarize current scientific evidence on the prevention and treatment of obesity and to develop statements on issues of clinical importance based on critical analysis of scientific literature.
September 30, 1992- Three obesity/nutrition research centers were established, along with an off-campus animal model nucleus, to breed genetically obese rats for obesity and diabetes research.
October 12, 1992— Institute fellows Drs. Edwin G. Krebs and Edmond H. Fischer, received the Nobel Prize in Physiology or Medicine for their work on reversible protein phosphorylation. At the time of the award, the scientists had received a continuing grant from the NIDDK since 1951 and 1956, respectively.
October 30, 1992—In response to congressional language, the NIDDK initiated a program to establish gene therapy research centers focused on cystic fibrosis.
September 1993—The NIDDK established the Cooperative Centers of Excellence in Hematology to generate collaborative research resources for research teams from a wide range of disciplines studying nonmalignant hematology.
1. November 1993—The functions of the NIH Department of Nutrition Research Coordination, including those of the NIH Nutrition Coordinating Committee, have been transferred to the NIDDK.
June 1994—In response to congressional language, the NIDDK established the Weight Management Information Network (WIN), an information service on obesity, weight management, and nutrition.
October 10, 1994- Dr Martin Rodbell and Alfred G. Gilman received the Nobel Prize in Physiology or Medicine for the discovery of G proteins, a key component in the signaling system that regulates cell activity. dr. Rodbell discovered the signaling function of GTP as a researcher at what was then NIAMD.
June 22, 1997—Under the leadership of the NIDDK, the NIH and the US Centers for Disease Control and Prevention (CDC) announced the establishment of the National Diabetes Education Program to promote the results of the multicenter Trial for Diabetes Control and Diabetes Complications (DCCT).
1998—The FDA approves the first effective therapy, hydroxyurea, forsickle cell anemiaResearch result of the current director of the NIDDK, Dr. Griffin P Rodgers.
1999—NIDDK-supported research resulted in the first FDA-approved productcontinuous glucose monitor(CGM), which allows people to track glucose levels in real time without having to prick their fingers.
1999—NIDDK established the Polycystic Kidney Disease Research Resource Consortium with a vision to accelerate the discovery of polycystic kidney disease through innovation and resource sharing.
July 18, 2000—The NIDDK created the National Kidney Disease Education Program to raise awareness about kidney disease and its risk factors and to provide educational resources to consumers and health care providers.
June 2000– The NIDDK created the Minority Health Research Coordination Office to develop the NIDDK Minority Health Strategic Plan to reduce minority health disparities.
November 16, 2000—The NIDDK celebrated its 50th anniversary.
2001-HeLook into the futurethe study begins. The study found that benefits of lifestyle intervention for people with long-standing type 2 diabetes include reducing sleep apnea, reducing the need for diabetes medications, helping to maintain physical mobility, and improving quality of life. of life.
June 2002- NIDDK launched the Summer Internship Program, now called the Diversity Summer Research Training Program (DSRTP), to increase enrollment of students from underrepresented backgrounds in biomedical research and to build a pipeline of research in the areas of NIDDK mission.
November 2002– The NIDDK established the Minority Health Research Investigators Network to increase the number of minority health researchers seeking NIH research support in areas of interest to the NIDDK.
2002– The NIDDK multisite study, theDiabetes Prevention Program(DPP) showed that moderate weight loss through diet changes and physical activity or the drug metformin can prevent or delay type 2 diabetes in people at high risk for the disease.
October 8, 2003—NIDDK fellow Dr. Peter Agre shared the Nobel Prize in Chemistry with another scientist for studying channels in cell membranes. Agre discovered aquaporins, proteins that transport water molecules across cell membranes.
4. October 2004-DR. Richard Axel, once an intern researcher for Dr. Gary Felsenfeld of the NIDDK, shared the Nobel Prize in Physiology or Medicine with another scientist for discovering a large family of receptors that are selectively expressed in cells that recognize specific odors.
October 6, 2004– Long-time NIDDK fellow, Dr. Irwin A. Rose and Avram Hershko shared the Nobel Prize in Chemistry with another scientist for discovering ubiquitin-mediated protein degradation within the cell.
October 2007-Dr. The Oliver Smithies Institute fellow shared the Nobel Prize in Physiology or Medicine with two other scientists for discovering principles for introducing specific genetic changes into mice using embryonic stem cells.
2008—Research by NIDDK fellows and grantees led torevolutionary discoverythat variants in a gene called APOL1 are associated with increased risk of kidney disease, and that these variants are found almost exclusively in people of African descent.
September 2010—NIDDK fellow Dr. Jeffrey Friedman and former fellow Dr. Douglas Coleman won the Albert Lasker Basic Medical Research Award for discovering the hormone leptin, which plays a key role in regulating energy intake and expenditure.
2010—The NIDDK celebrated its 60th anniversary.
3. October 2011—NIDDK fellow Dr. Bruce Beutler shared the Nobel Prize in Physiology or Medicine with Dr. Jules Hoffman for their discoveries on the activation of innate immunity. NIH recipient Dr. Ralph Steinman also shared the award posthumously for his discovery of the dendritic cell and its role in adaptive immunity.
December 2011-The newspaperSciencenamed one of the NIDDK members, Dr. Myron Cohen led the 2011 Breakthrough HIV Prevention Research Study. The study found that people infected with HIV reduced the risk of transmitting the virus to their sexual partners by taking oral antiretroviral drugs when their immune systems were relatively healthy.
April 29, 2012- Results of the Treatment Options for Type 2 Diabetes in Adolescents and Adolescents (TODAY) study appeared in theNew England Journal of Medicine, which is the first large comparative efficacy study in the treatment of type 2 diabetes in young people. The NIDDK-funded study found that the combination therapy of metformin and rosiglitazone was superior to metformin alone.
September 21, 2012-DR. Thomas E. Starzl, a long-time NIDDK fellow, received the Lasker-DeBakey Clinical Medical Research Award, which he shared with another scientist for their work in developing liver transplantation, an intervention that has brought normal life to thousands of people with end-stage disease. liver disease brought him back to life.
October 2012-DR. Robert J. Lefkowitz, who trained at NIDDK as a clinical associate in the Department of Clinical Endocrinology, won the Nobel Prize in Chemistry for studies of protein receptors, which direct cells in the body to sense and respond to external signals.
October 2013– NIDDK fellow Dr. James Rothman shared the Nobel Prize in Physiology or Medicine with fellow NIH fellows Dr. Randy W. Schekman and Thomas C. Südhof for discovering the mechanisms that regulate vesicle trafficking, an important system of transport in our cells.
1. August 2015—NIDDK established the Office of Nutrition Research, replacing the NIH Division of Nutrition Research Coordination, to help lead an inter-NIH group to strategically plan new initiatives for NIH nutrition research.
2015-HeChronic kidney disease cohort(CRIC) published results showing that elevated blood levels of one of two proteins are associated with up to an 11-fold increased risk of heart failure in patients with chronic kidney disease (CKD).
September 2016—NIDDK fellow Dr. Gregg L. Semenza shared the Albert Lasker Basic Medical Research Award with NIH fellow Dr. William G. Kaelin Jr. and another scientist for their discovery of how human cells and most animals sense and adapt to changes in oxygen availability, a process essential for survival.
march 2018—The NIDDK launched the Office of Clinical Research Support (OCRS), a virtual office to oversee and coordinate the development of policies and procedures for NIDDK-funded clinical trials.
September 2018-DR. Adriaan "Ad" Bax, NIDDK Department ManagerChemical Physics Laboratory, received the Robert A. Welch Prize in Chemistry for his contributions to transforming NMR spectroscopy to study the structure and dynamics of biological macromolecules.
7. October 2019—NIDDK Fellow Dr. Gregg L. Semenza shared the Nobel Prize in Physiology or Medicine with NIH Fellow Dr. William G. Kaelin Jr. and another scientist for discovering how cells sense and adapt to the availability of oxygen.
January 2020—NIDDK streamlined and integrated its information clearinghouses and educational programs under the NIDDK umbrella.
april 2020- NIDDK research shows the importance of masks in the transmission of COVID-19. NIDDK Intramural researchers have found that speaking produces as many or more droplets than coughing or sneezing and that wearing a simple face covering keeps most potentially SARS-CoV-2-infected speech particles at their source.
mayo 2020— Led by Nutrition Research Task Force Chair Dr. Griffin P. Rodgers, and with support from the NIDDK Office of Nutrition Research, the first NIH Strategic Plan for Nutrition Research was published, emphasizing innovative and cross-sector opportunities in precision nutrition.
2020—The NIDDK celebrated its 70th anniversary.
January 2021The Office of Nutrition Research will be transferred to the NIH Office of the Director, Department of Program Coordination, Planning and Strategic Initiatives to implement the 2020-2030 Strategic Plan for NIH Nutrition Research.
Timeline of NIDDK legislation
December 11, 1947—The Institute of Experimental Biology and Medicine was incorporated under Public Law Section 202 (PL) 78-410.
August 15, 1950—The Omnibus Medical Research Act (PL 81-692) established the National Institute of Arthritis and Metabolic Diseases (NIAMD) to “…investigate the cause, prevention, and methods of diagnosis and treatment of arthritis and rheumatism and assist and encourage others to carry out metabolic diseases and encourage such research and other activities by public and private agencies and promote the coordination of all such research and provide training in matters relating to such diseases..." Section 431 also authorized the US Surgeon General to establish a national advisory board.
May 19, 1972—PL 92-305 again emphasized digestive disease research, changing the institute's name to the National Institute of Arthritis, Metabolism, and Digestive Diseases (NIAMDD) and naming a Digestive Diseases Committee within the institute's National Advisory Council.
July 23, 1974—The National Diabetes Mellitus Research and Education Act (P.L. 93-354) was enacted. The National Diabetes Commission authorized by this Act was established on September 17, 1974. The Act authorized diabetes research and education centers and an interstate diabetes coordinating committee that included representatives from NIAMDD and six other NIH institutes.
January 1975—The National Arthritis Act of 1974 (P.L. 93-640) was enacted to promote research, education, and training in the field of connective tissue disorders. The law authorized the establishment of a national commission, research and training centers on arthritis and rheumatic diseases, a database and a general plan to study the epidemiology, etiology, control and prevention of these diseases.
October 1976—The Arthritis, Diabetes, and Digestive Diseases Amendments of 1976 (P.L. 94-562) established the National Diabetes Advisory Board charged with advising Congress and the Secretary of Health, Education, and Human Services (HEW) on implementationLong-term plan to combat diabetesDeveloped by the National Diabetes Commission. The law also established the National Commission on Digestive Diseases to study the incidence, duration, mortality rates, and social and economic impact of digestive diseases.
December 1980– Title II of the Health Program Extension Act of 1980, P.L. 96-538, changed the institute's name to the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases. The law also established the National Digestive Diseases Advisory Board. The law authorized the National Diabetes Information Center, the Diabetes Data Group, and the National Digestive Diseases Information and Education Center. In addition, it has reauthorized advisory boards for arthritis and diabetes research.
November 20, 1985– The Health Research Extension Act of 1985 (PL 99-158) changed the Institute's name to the National Institute of Diabetes and Digestive and Kidney Diseases. The law also established the National Advisory Board on Kidney and Urologic Diseases. The law gave parallel special powers to all of the institute's operating departments, including approval of the National Clearinghouse for Urological and Kidney Diseases; National Coordinating Committee for Renal, Urological and Hematological Diseases; National Data System for Renal and Urological Diseases; National Data System for Digestive Diseases; research centers for renal and urological diseases; and research centers for digestive diseases.
June 10, 1993- The NIH Revitalization Act of 1993 (PL 103-43) established the NIDDK as the leading institution in eating disorders and obesity, including the establishment of an eating disorders and obesity research and training center program. The law also required the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging, the National Institute of Dental Research, and the NIDDK to conduct research and programs related to osteoporosis, Paget's disease, and related diseases. Bones expand and intensify disorders.
July 25, 1997- A report from the House of Representatives that H.R. 2264, and a Senate report at page 1061, FY 1998 Approval Bills for Labor/HHS/Education, called for the NIH and NIDDK to establish a Diabetes Research Task Force to develop a comprehensive plan for diabetes research. NIH-funded diabetes for future initiatives and recommend directions. dr. C. Ronald Kahn, Chairman of the Diabetes Research Task Force, presented "Conquering Diabetes, A Strategic Plan for the 21st Century" to Congress on March 23, 1999.
5. August 1997—The Balanced Budget Act of 1997 (P.L. 105-33), as immediately amended by the Taxpayer Relief Act of 1997 (P.L. 105-34), introducedSpecial statutory funding program for type 1 diabetes research(now Section 330B of the Public Health Service Act). This legislation provided $30 million per year from fiscal year 1998 through fiscal year 2002. (The program was renewed and funding increased in subsequent years.) This funding program augments the regularly allocated funds that HHS receives for diabetes research through the Laboratory-HHS-Education subcommittee funds. The NIDDK, through authority granted by the Secretary of HHS, guides the planning, administration, and evaluation of these funds. Parallel toSpecial statutory funding program for type 1 diabetes research, P. L. 105-33 also established theSpecial Diabetes Program for Indians, administered by the Indian Health Service.
October 17, 2000—Title IV, Section 402 of the Children's Health Act of 2000 (P.L. 106-310), titled "Reducing the Burden of Diabetes Among Children and Youth," stipulates that the NIH conduct long-term epidemiological studies, support regional centers clinical research, and provide a national prevention effort related to type 1 diabetes.
December 21, 2000—The Fiscal Year 2001 Consolidated Appropriations Act (P.L. 106-554) increased appropriations for theSpecial legal support program for type 1 diabetes researchto $100 million per year for fiscal years 2001 and 2002 and renewed the program at $100 million for fiscal year 2003.
December 17, 2002—The Diabetes Research-Related Public Health Service Amendment Act (P.L. 107-360) expanded and supplemented theSpecial statutory funding program for type 1 diabetes research. The law appropriated $150 million annually for type 1 diabetes research from fiscal year 2004 through fiscal year 2008.
December 8, 2003- Title VII, Subtitle D, Section 733 of the Medicare Prescription Drug and Modernization Improvement Act of 2003 (PL 108-173) authorized the NIDDK to conduct a clinical trial of pancreatic islet transplantation involving recipients of Medicare. Medicare would pay for routine expenses, transplants, and appropriate related items and services for Medicare beneficiaries participating in the study.
October 25, 2004- The Pancreatic Islet Transplantation Act of 2004 (PL 108-362) amended the Public Health Services Act to increase the supply of pancreatic islet cells for research and to better coordinate federal efforts and enable information on islet cell transplantation. A provision of this law required that annual reports prepared by the NIDDK-led Interagency Diabetes Mellitus Coordinating Committee include an evaluation of federal activities and programs related to pancreatic islet transplantation.
September 2004- Reports accompanying the FY 2005 Senate and House Labor, HHS, and Education bills (Senate Report 108-345 and House Report 108-636) called for NIH to and HHS to establish a national commission on digestive diseases to establish a long-term outreach research plan. The NIH director then established the National Commission on Digestive Diseases in August 2005 under the leadership of the NIDDK.
December 29, 2007- The Medicare, Medicaid, and SCHIP Extension Act of 2007 (PL 110-173) extended funding for the specialLegal Funding Program for Type 1 Diabetes Research. The law provided $150 million for type 1 diabetes research in fiscal year 2009.
July 15, 2008—The Patient and Provider Medicare Improvement Act of 2008 (PL 110-275) expanded funding for theSpecial statutory funding program for type 1 diabetes research. The law provided $150 million annually for type 1 diabetes research in fiscal years 2010 and 2011.
February 17, 2009—The American Recovery and Reinvestment Act (ARRA) of 2009 (PL 111-5) provided the NIH with a two-year cash injection. The NIDDK developed a plan to use its portion of the ARRA funds to meet the stimulus targets set forth in the Recovery Act. This funding supported a number of biomedical research efforts as part of the institute's research mission.
June 15, 2010-H. Resolution 1444 introduced a bipartisan resolution recognizing the 60th anniversary of the NIDDK.
December 15, 2010—The Medicare and Medicaid Extension Act of 2010 (PL 111-309) expanded funding for theSpecial statutory funding program for type 1 diabetes research. The law provided $150 million annually for type 1 diabetes research in fiscal years 2012 and 2013.
January 2, 2013—The American Taxpayer Relief Act of 2012 (P.L. 112-240) expanded funding for theSpecial statutory funding program for type 1 diabetes research. The law provided $150 million for type 1 diabetes research in fiscal year 2014.
April 1, 2014—The Medicare Access Protection Act of 2014 (P.L. 113-93) expanded theSpecial statutory funding program for type 1 diabetes research. The law provided $150 million for type 1 diabetes research in fiscal year 2015.
April 16, 2015—The CHIP and Medicare Access Reauthorization Act of 2015 (P.L. 114-10) expanded theSpecial statutory funding program for type 1 diabetes research. The law appropriated $150 million per year for type 1 diabetes research in fiscal years 2016 and 2017.
February 9, 2018—The Bipartisan Budget Act of 2018 (P.L. 115-123) expanded theSpecial statutory funding program for type 1 diabetes research. The law appropriated $150 million per year for type 1 diabetes research in fiscal years 2018 and 2019.
March 27, 2020– Der Coronavirus Aid, Relief, and Economic Security (CARES) Act (PL 116-136) erweiterte dieSpecial statutory funding program for type 1 diabetes research. The law provided $150 million for type 1 diabetes research in fiscal year 2020.
December 27, 2020—The Consolidated Appropriations Act of 2021 (P.L. 116-260) expanded theSpecial statutory funding program for type 1 diabetes research. The law appropriated $150 million annually for type 1 diabetes research from fiscal year 2021 through fiscal year 2023.
Biographical Sketch of NIDDK Director Griffin P. Rodgers, M.D., M.A.C.P.
Griffin P. Rodgers, MD, MACP
dr. Griffin P. Rodgers was appointed Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), one of the National Institutes of Health (NIH), on April 1, 2007. He has been deputy director of the NIDDK since March 2006 and has he has been deputy director of the institute since January 2001. As director of the NIDDK, Dr. Rodgers provides scientific leadership and manages more than 630 employees and a budget of nearly $2.25 billion.
dr. Rodgers received his bachelor's, master's, and medical degrees from Brown University in Providence, Rhode Island. He completed his residency and internal medicine residency at Barnes Hospital and Washington University School of Medicine in St. Louis. His fellowship training in hematology was in a joint NIH program with George Washington University and the Washington Veterans Administration Medical Center. In addition to her medical and scientific training, she earned an MBA with an emphasis in Business of Medicine/Science from Johns Hopkins University in 2005.
As a researcher, Dr. Rodgers is widely recognized for her contributions to the development of the first effective, and now FDA-approved, therapy for sickle cell disease. She has been a principal investigator in clinical trials to develop a therapy for patients with sickle cell disease and has also conducted basic research focused on understanding the molecular basis of how certain drugs induce gamma globin gene expression. More recently, he and her colleagues reported a modified blood stem cell transplant regimen that is highly effective in reversing sickle cell disease in adults and is associated with relatively low toxicity. She has received numerous awards for her research, including the 1998 Richard and Hinda Rosenthal Foundation Award, the 2000 Arthur S. Flemming Award, the 2002 Legacy of Leadership Award, and a 2005 Master's degree from the American College of Physicians. . 2018 Dr Rodgers was elected a Fellow of the American Association for the Advancement of Science and the Royal College of Physicians (London).
dr. Rodgers has been a visiting professor at medical schools and hospitals both at home and abroad. He has been honored with many teaching positions at American medical centers and has published more than 250 original research articles, reviews, and book chapters; he has edited four books and monographs; and holds three patents.
dr. Rodgers is a member of the American Society of Hematology, the American Society for Clinical Research, the American Medical Association, the American Academy of Arts and Sciences, and the National Academy of Medicine, among others. He has served as Governor of the American College of Physicians and as Chairman of the Subspecialty Board of Hematology and as a member of the Board of Directors of the American Board of Internal Medicine.
dr. Rodgers serves as chair, co-chair, and member of numerous high-level trans-NIH and HHS scientific and administrative committees. He is chair of the NIH Nutrition Research Task Force, co-chair of the NIH Obesity Research Task Force, and a member of the Executive Committee that runs the Accelerated Medications Association. He is also co-director of the NIH Common Fund's Illuminating the Druggable Genome program and is a member of the NIH Steering Committee, the Joint Leadership Council of the NIH and the Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services. (CMS) of the NIH. Leadership Council, among others.
NIDDK Directors
| Name | in office of | A |
|---|---|---|
| William Henry Sebrell Jr.. | August 15, 1950 | October 1, 1950 |
| russell m. wilder | March 6, 1951 | June 30, 1953 |
| Floyd S. Daft | October 1, 1953 | 3. mayo 1962 |
| G.Donald Whedon | November 23, 1962 | 30.09.1981 |
| Lester B. Salans | June 17, 1982 | June 30, 1984 |
| Mortimer B. Lipstick | January 7, 1985 | 4. September 1986 |
| Felipe Gorden | 5. September 1986 | November 14, 1999 |
| Allen M mirror | November 15, 1999 | March 3, 2006 |
| griffin p rodgers | April 1, 2007 | At the moment |
Program
Department of Intramural Investigations (DIR)
HeThe NIDDK Intramural Research Programconducts biomedical research and education related to diabetes, endocrine and metabolic disorders, including liver disease and nutrition, obesity, and renal, urinary, and hematologic disorders at its laboratories and clinical facilities in Bethesda, Maryland, and Phoenix, Arizona . The research carried out at DIR covers the spectrum of modern biomedical research, from basic research to clinical studies.
Department of Diabetes, Endocrinology and Metabolic Diseases (DEM)
HeDepartment of Diabetes, Endocrinology and Metabolic Diseasesprovides funding and support for basic and clinical research in the areas of type 1 and type 2 diabetes and other metabolic diseases, including cystic fibrosis; endocrinology and endocrine disorders; obesity, neuroendocrinology and energy balance; and development, metabolism, and basic biology of liver, adipose, and endocrine tissue. DEM also provides funding for the training and professional development of individuals pursuing clinical research and academic careers in these areas.
Division of Digestive Diseases and Nutrition (DDN)
HeDepartment of Digestive Diseases and Nutritionsupports research related to diseases of the digestive tract, including the digestive tract, liver and pancreas, nutrition, and obesity. Programs include basic research, translational and clinical research, research training, and professional development. DDN also promotes public awareness and education about digestive and related diseases.
Clinical Department of Renal, Urological and Hematological Diseases (KUH)
HeDepartment of Renal, Urological and Hematological Diseasesprovides research funding and support for pivotal, translational, and clinical research studies in kidney, urinary tract, and diseases of the blood and blood-forming organs. The department also provides funding for the training and professional development of individuals engaged in these areas of academic and clinical research.
Department of Extracurricular Activities (DEA)
HeExtracurricular Activities Departmentprovides leadership, oversight, tools, and guidance to manage the extracurricular activities of the NIDDK, including efforts related to the academic peer review process for evaluating grant applications and grant release and administration. The DEA also coordinates the administration activities of the NIDDK committee andAdvisory Boardmeetings and conducts and coordinates programmatic analysis and evaluation activities.
NIDDK Director's Office
HeNIDDK Director's Officeprovides scientific and administrative leadership for the Institute, including policy guidance, strategic program development and evaluation, and overall operational and administrative coordination.
The Director's Office also administers the following research grant programs:
- Clinical Research Support Office
- biostatistics program
- Regulatory Support Program
- NIDDK Central Repository
Workshop (EO)
HeNIDDK Executive Officeit is the central point of contact for the administrative infrastructure and functions of the institute. The office provides strategic leadership, direction, supervision, and advice on critical business and managerial operations and works with program scientists and staff in support of the NIDDK mission. The office oversees administrative management, financial management, procurement and purchasing, ethics, information technology, and human resource development and planning. It also develops and implements administrative policies, procedures, and risk management programs.
Office for Minority Health Research Coordination (OMHRC)
HeOffice for the Coordination of Minority Health Researchdeals with diseases and disorders that disproportionately affect minorities. OMHRC oversees the implementation of the Institute's Strategic Plan on Health Disparities and is based on a partnership with the NIH's National Institute on Minority Health and Health Disparities. OMHRC also develops initiatives to train new and early-stage investigators who are underrepresented in biomedical research. The OMHRC also tracks and evaluates the Institute's progress in educating underrepresented racial and ethnic minorities in biomedical research.
Office for Obesity Research
HeOffice for Obesity Researchcoordinates obesity-related research within the NIDDK and carries out its tasks through the NIDDK Obesity Research Task Force. The co-chairs represent the two departments primarily responsible for obesity-related non-university research: DDN and DEM.
The Obesity Research Task Force includes representatives from DDN, DEM, KUH, the NIDDK Review Branch, the Office for Scientific Policy and Program Analysis (OSPPA), and the Office of Communications and Public Liaison (OCPL). the working group
- provides a forum for the exchange and coordination of trans-NIDDK and trans-NIH obesity research activities
- assists the NIDDK director in identifying research opportunities, initiatives, and breakthroughs
- identifies and plans workshops and conferences
- prepares reports and research related to obesity
Office of Communications and Public Relations (OCPL)
HeNIDDK Office of Communications and Public Relationsexplains, translates, and promotes research related to the NIDDK. OCPL responds to requests from the public and the media and reaches a broad and targeted audience with health awareness and prevention messages. OCPL strives to be compassionate, cooperative, transparent and accountable in all interactions and to be vigilant and responsible in the use of public funds and public trust. OCPL offers
- health informationfor patients, healthcare professionals, and the general public seeking information on NIDDK topics
- Response to media inquiryfor reportersFind information from the NIDDK, including interviews with scientists
- it means thatContact Usfor questions or requests
Office of Scientific Program and Policy Analysis (OSPA)
HeNIDDK Office for Scientific Program and Policy Analysiscoordinates, analyzes, and writes scientific program reports, briefing materials, and other documents, including the annual NIDDK Recent Advances & Emerging Opportunities report. These documents present the NIDDK's scientific achievements and plans to policymakers, including Congress; the scientific community; voluntary health organizations; and other target groups. OSPPA advises the NIDDK Director and senior scientific leadership on strategic planning, evaluation approaches, and science policy issues. OSPPA also serves as a point of contact for dialogue with representatives of professional and patient groups and Congressional staff.
Technological Advancement Office (TAO)
HeNIDDK Office of Technology Advancementreviews, writes, and negotiates various settlements for members of the global scientific community who wish to access research materials developed by NIDDK scientists and/or collaborate with the NIDDK on a clinical trial or other research work. In addition, TAO evaluates invention disclosures provided by the institute's research staff, makes decisions regarding the filing of patent applications for discoveries and inventions, and assists with product development strategy.